Press Release | August 09, 2020

Minapharm Announces Appointment of Two New Board Members

Shaheer has been appointed as an Executive Board Member. His knowledge and expertise in advanced medicinal therapies, as well as his global network in academia and industry will serve the natural expansion of Minapharm’s pioneering position in biopharmaceuticals as it continues to place itself for next generation medicines. Shaheer is assigned the responsibility to establish and develop Minapharm’s growth strategy in the field of immuno-oncology and gene and cell-based therapies in collaboration with Minapharm’s subsidiaries in Cairo and Berlin.

Dr. Shaheer Bardissi worked for five years at BioNTech SE, one of Europe’s largest biotech firms and world leader in personalized cancer immunotherapy. He served in the successful development of immunotherapeutic technologies in the cell and gene therapy group lead by Prof. Dr. Ugur Sahin, a world-leading onco-immunologist and BioNTech’s CEO. Shaheer obtained his PhD from Johannes Gutenberg University, Mainz, Germany, with a focus on gene-based immunotherapy. Prior to that, he completed his Master of Science in Molecular Medicine at University College London and his Bachelor of Science in Biomedical Sciences at King’s College London. He is currently a member of the Management Science program in Quantitative Healthcare Business Analytics at Duke University, North Carolina, USA.

Tarek has been appointed as an Independent Board Member bringing more than 15 years of experience in investing in emerging markets with a track record of building regional and global leading companies out of the Middle East and Africa. In his role, Tarek will support one of Minapharm’s visions of identifying, acquiring and integrating pharma players regionally and internationally as well as maintaining its leading position in the biopharmaceutical industry.

Mr. Tarek Mounib is a founder and Partner at East Lane Partners, a newly established private equity firm with a primary focus on emerging markets investments.He was the Head of Private Equity at NBK Capital Partners and a member of the Investment Committee of its private equity business. Prior to NBK Capital Partners, he was previously a Managing Director at Gulf Capital. He served on the Board of Directors of multiple domestic and regional companies in the MENA region. Tarek holds a B.A. in Economics from the American University in Cairo and an M.B.A. from the Yale School of Management. He is also a CFA charter-holder.

About MINAPHARM– – Backed with half a century of experience, Minapharm is a leading pharmaceutical and the first and only biopharmaceutical company in Egypt, Africa and the Middle East. Headquartered in Cairo, the company maintains a portfolio of more than 150 of the broadest quality products within the industry. The longstanding expertise covers a broad spectrum of medicines, ranging from small molecules to extremely complex bioengineered proteins, with an ultimate goal of striking the balance between innovation and affordability. Minapharm export activities include more than 14 countries in the Gulf and Africa. The company employs over 2000 full-time employees and is listed on Egyptian Stock Exchange (symbol: MIPH).